SK Biopharmaceuticals said on the 12th that sales of the epilepsy treatment Cenobamate in the United States last year totaled 630.3 billion won. That was up 44% from a year earlier. The company plans to expand prescription share this year with tailored marketing for medical professionals.
SK Life Science, the U.S. subsidiary of SK Biopharmaceuticals, recently held the "2026 National Sales Meeting" in Florida and disclosed these details. The meeting marked its seventh year. President Lee Dong-hoon of SK Biopharmaceuticals and about 290 executives and employees attended to share goals and plans.
This year's key message is "one team" synergy. The headquarters and the U.S. subsidiary will work together in the same direction in research and development, strategy, and marketing. The company plans to expand its business beyond Cenobamate into oncology. It will hold lectures and workshops for patients and medical professionals.
Cenobamate received approval from the U.S. Food and Drug Administration (FDA) in 2019. Since the following year, SK Life Science has been selling it in the United States under the name Xcopri. President Lee Dong-hoon said, "Based on our shared goals, we will break down organizational boundaries and move in the same direction," adding, "We will pursue business expansion, leveraging the success of Cenobamate."